{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:51:48Z","timestamp":1784674308807,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"15","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100006107","name":"Gil Medical Center, Gachon University","doi-asserted-by":"publisher","award":["GCU\u2010202309950001"],"award-info":[{"award-number":["GCU\u2010202309950001"]}],"id":[{"id":"10.13039\/501100006107","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      TS\u20101 at 80\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day for 4\u2009weeks followed by a 2\u2010week rest is standard adjuvant therapy for stage II\/III Advanced Gastric Cancer (AGC). TS\u20101 for 1\u2009year (8 courses) is highly recommended. We investigated the efficacy and safety of an adjuvant 3\u2010weekly TS\u20101 regimen for AGC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed 93 patients with stage II\/III AGC who started 3\u2010weekly adjuvant TS\u20101 therapy between Feb 2017 and May 2022 post\u2010gastrectomy with D2 lymphadenectomy. The 3\u2010weekly regimen was TS\u20101 at 80\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      \/day for 2\u2009weeks, followed by a 1\u2010week rest for 1\u2009year (16 courses).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 93 patients, 12 (13%) had disease recurrence during follow\u2010up (median 24.6 months, range 4.2%\u201363.3%). Seven (9.5%) with stage II (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200973) and five (25%) with stage III (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920) experienced recurrence. Kaplan\u2013Meier analysis estimated that Recurrence\u2010Free Survival (RFS) rates at 1, 3, and 5\u2009years were 92.0% (95% CI; 86.5%\u201397.9%), 84.7% (95% CI; 76.4%\u201393.9%), and 78.6% (95% CI; 65.8%\u201394.0%), respectively. Eighty patients (86%) completed the treatment; 25 (26.9%) needed dose reduction. Adverse events, mostly grade 1 or 2 diarrhea (28%) and nausea (20%), were manageable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study revealed that the 3\u2010weekly TS\u20101 regimen as adjuvant therapy exhibited good efficacy and manageable toxicity. This regimen as an adjuvant therapy for AGC should be evaluated in future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71079","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T10:34:29Z","timestamp":1753958069000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of a 3\u2010Weekly\n                    <scp>TS<\/scp>\n                    \u20101 Adjuvant Regimen in Advanced Gastric Cancer: A Pilot Study"],"prefix":"10.1002","volume":"14","author":[{"given":"Jihong","family":"Bae","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo\u2010Hwan","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Saing","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Kyung","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Kyung","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Bok","family":"Shin","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u2010Hyeon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Surgery Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun\u2010Young","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Surgery Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woon Kee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jin","family":"Sym","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine Gachon University Gil Medical Center  Incheon Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v11.i9.679"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010187"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.5908"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70473-5"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-011-0003-y"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.e14580"},{"key":"e_1_2_10_12_1","first-page":"2167","article-title":"Phase II study of 2\u2010week TS\u20101 administration followed by 1\u2010week rest for gastric cancer","volume":"54","author":"Imamura H.","year":"2007","journal-title":"Hepato\u2010Gastroenterology"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.381"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072252"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70035-4"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2015.15.2.113"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2016.569"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-004-0278-3"},{"issue":"3","key":"e_1_2_10_19_1","first-page":"17","article-title":"Clinical implications of dihydropyrimidine dehydrogenase inhibition","volume":"13","author":"Diasio R. B.","year":"1999","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2016\/19345.8776"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902729412"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0959\u20108049(98)00211\u20101"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000012099"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.4174\/jkss.2011.81.3.163"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1935-6"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2022.22.e6"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3001"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-023-01419-9"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i1.310"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71079","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71079","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:12:19Z","timestamp":1772989939000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/cam4.71079"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71079","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"2024-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71079"}}